DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS 19.08.2024 / 16:00 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________

CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE

 

DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS

 

Vancouver, BC, Canada, August 19th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benefit of using the Accum technology to increase the  half-life and efficacity of the GLP-1 agonist as a treatment for obesity and related comorbidities (type 2 diabetes).

Obesity is one of the most urgent health challenges in the world with extensive comorbidities, such as type 2 diabetes, cardiovascular diseases, steatohepatitis and chronic kidney disease to name a few. Over four billion people - about 50% of the world’s population - are estimated to be impacted by obesity or being overweight by 2035. According to WHO, more than one billion people are obese including 650 million adults, 340 million adolescents and 39 million children. The growing number puts an incredible strain on societies and healthcare systems around the world. With the development of revolutionary drugs able to reduce the body weight by 15% to 20% of overweight and obese patients, this could be the biggest opportunity that the pharma industries have ever seen.